Beremagene geperpavec Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Beremagene geperpavec Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Approved
Highest phase
5
Registered trials
5
Result records
1
Matched deals
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Beremagene geperpavec can convert its Gene therapy profile and COL7A1 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Beremagene geperpavec (query alias: beremagene) |
|---|---|
| Modality / target | Gene therapy; COL7A1; COL7A1 gene transference |
| Highest global status | Approved |
| Originator | Krystal Biotech, Inc. |
| Active developers | Krystal Biotech, Inc. |
The MCP disease footprint includes Epidermolysis Bullosa Dystrophica, Corneal Injuries. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT04917874 | Phase 3 | Completed | 47 | To record safety outcomes of participants while on B-VEC. |
| NCT04491604 | Phase 3 | Completed | 31 | Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 |
| NCT07016750 | Phase 3 | Recruiting | 16 | To evaluate the safety and tolerability of KB803. |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
FDA-Approved Drugs-VYJUVEK-CLINICAL STUDIES (II)
Phase 1/2; n=not disclosed; evaluation: Positive. Reported fields: TEAE = Thirty-five treatment-emergent adverse events (TEAEs) were reported in 9 of the 12 subjects.Among the 35 TEAEs, the Applicant considers 19 as probable or possible drug-related AEs in five subjects. ; TEAE = Thirty-five treatment-emergent adverse events (TEAEs) were reported in 9 of the 12 subjects.Among the 35 TEAEs, the Applicant considers 19 as probable or possible drug-related AEs in five subjects.
FDA-Approved Drugs-VYJUVEK-CLINICAL STUDIES (I)
Phase 3; n=not disclosed; evaluation: Positive. Reported fields: Complete wound closures(at Weeks 22 & 24 or Weeks 24 & 26) = 25.8 % ; Complete wound closures(at Weeks 22 & 24 or Weeks 24 & 26) = 64.5 %
A Phase III Efficacy and Safety Study of Beremagene Geperpavec (B-VEC, Previously "KB103") for the Treatment of Dystrophic Epidermolysis Bullosa (DEB)
Phase 3; n=31; evaluation: not stated. Reported fields: Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26 = 6.7 number of wounds with complete healing ; Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26: responder rate difference = 45.8(95% CI, 23.6 - 68.0), P-Value = 0.00192; Primary Wound With Complete Wound Healing (100% Wound Closure) on Weeks 22 and 24 or Weeks 24 and 26: responder rate difference = 45.8(95% CI, 23.6 - 68.0), P-Value = 0.00192
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Beremagene geperpavec addresses Epidermolysis Bullosa Dystrophica, Corneal Injuries. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Gene therapy—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-09-25 | Swixx Signs Agreement With Krystal Biotech For Vyjuvek® Gene Therapy For The Treatment Of Dystrophic Epiderolysis Bullosa | Approved | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 15 July 2026. Counts and status fields may change as source records update.
